Avistone’s Met challenge
The company starts a China phase 3 of andamertinib in EGFR-mutant, Met-amplified NSCLC.
FDA red and green lights: February 2025
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
SpringWorks is in the air for Merck KGaA
The deal isn’t done, but would be Merck’s biggest oncology buy.
